<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01343706</url>
  </required_header>
  <id_info>
    <org_study_id>1289.1</org_study_id>
    <secondary_id>2010-023604-27</secondary_id>
    <nct_id>NCT01343706</nct_id>
  </id_info>
  <brief_title>Safety Tolerability and Pharmacokinetic of BI 409306</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled (Within Dose Groups) Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Doses 0.5 mg to 500 mg of BI 409306 Administered Orally in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of the current study is to investigate the safety and tolerability of
      BI 409306 in healthy male genotyped volunteers following oral administration of single rising
      doses.

      The secondary objectives are: (1) to explore dose proportionality of BI 409306 as immediate
      release solid oral dosage, (2) to explore the relative bioavailability of BI 409306 when
      administered as immediate release solid oral dosage compared to oral drinking solution and
      (3) to compare the safety and pharmacokinetic profiles between two different groups of
      genotyped subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Physical examination (respiratory, gastro-intestinal, musculoskeletal)</measure>
    <time_frame>18 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs</measure>
    <time_frame>18 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>12-lead ECG (electrocardiogram)</measure>
    <time_frame>18 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory tests (haematology: haemoglobin; haematocrit/erythrocytes; haemoglobin/erythroctes; Erythro-, leuco-,lympho-, mono-Cytes; Platelets)</measure>
    <time_frame>18 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>18 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of tolerability by investigator</measure>
    <time_frame>18 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory tests (clinical chemistry: electrolytes;liver enzymes, bilirubin, amylase, lipase, cholesterol)</measure>
    <time_frame>18 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory tests (urinanalysis: pH, nitrite, protein, glucose, ketones, red blood cells, white blood cells, bacteria, crystals)</measure>
    <time_frame>18 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in Bond-Lader Visual Analogue Scales</measure>
    <time_frame>Up to 24 h after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of the analyte in plasma from time 0 to time of last quantifiable data point)</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aet1-t2 (amount of analyte eliminated in urine from the time point t1 to time point t2)</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 409306 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solution for oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 409306 lowdose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solution for oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 409306 medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solution for oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 409306 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immediate release solid oral dosage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 409306 medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immediate release solid oral dosage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 409306 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immediate release solid oral dosage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solution for oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo .</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immediate release solid oral dosage</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Solution for oral administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo .</intervention_name>
    <description>Immediate release solid oral dosage</description>
    <arm_group_label>Placebo .</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 409306</intervention_name>
    <description>Immediate release solid oral dosage medium</description>
    <arm_group_label>BI 409306 medium dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 409306</intervention_name>
    <description>Immediate release solid oral dosage low</description>
    <arm_group_label>BI 409306 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 409306</intervention_name>
    <description>Immediate release solid oral dosage high</description>
    <arm_group_label>BI 409306 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 409306</intervention_name>
    <description>low dose solution for oral administration</description>
    <arm_group_label>BI 409306 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 409306</intervention_name>
    <description>low dose solution for oral administration</description>
    <arm_group_label>BI 409306 lowdose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 409306</intervention_name>
    <description>medium dose solution for oral administration</description>
    <arm_group_label>BI 409306 medium dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy males according to the following criteria: Based upon a complete medical
             history, including the physical examination, vital signs (blood pressure (BP), pulse
             rate (PR)), 12-lead electrocardiogram (ECG), clinical laboratory tests

          2. Age &gt; 21 and Age &lt; 50 years

          3. Body Mass Index (BMI) &gt; 18.5 and BMI &lt; 29.9 kg/m2

        Exclusion criteria:

          1. Any finding of the medical examination (including BP, PR and ECG) deviating from
             normal and of clinical relevance

          2. Any evidence of a clinically relevant concomitant disease

          3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          4. Surgery of the gastrointestinal tract (except appendectomy)

          5. Diseases of the central nervous system (including but not limited to any kind of
             seizures, stroke or psychiatric disorders) within the past 6 month

          6. History of relevant orthostatic hypotension, fainting spells or blackouts.

          7. Chronic or relevant acute infections

          8. History of relevant allergy/hypersensitivity (including allergy to drug or its
             excipients)

          9. Use of drugs which might reasonably influence the results of the trial or that prolong
             the QT/QTc interval based on the knowledge at the time of protocol preparation within
             10 days prior to administration or during the trial

         10. Any laboratory value outside the reference range that is of clinical relevance

         11. A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a
             QTc interval &gt;450 ms);

         12. A history of additional risk factors for Torsades de points (TdP) (e.g., heart
             failure, hypokalemia, family history of Long QT Syndrome)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1289.1.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ingelheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2011</study_first_submitted>
  <study_first_submitted_qc>April 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2011</study_first_posted>
  <last_update_submitted>October 31, 2013</last_update_submitted>
  <last_update_submitted_qc>October 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

